A Phase I Dose Escalation, Multi-Center, Open-Label Study of HSP990 Administered Orally in Adult Patients With Advanced Solid Malignancies.
Phase of Trial: Phase I
Latest Information Update: 27 Jan 2015
At a glance
- Drugs HSP 990 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 23 Aug 2012 Status changed from active, no longer recruiting to completed.
- 27 Apr 2012 Actual patient number is 64 as reported by ClinicalTrials.gov.
- 27 Apr 2012 Planned end date changed from 1 Jun 2012 to 1 May 2012 as reported by ClinicalTrials.gov.